AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 27.2% according to Barclays.
Barclays set a target price of 13,500 GBX for the company, which when compared to the AstraZeneca plc share price of 10,614 GBX at opening today (19/09/2023) indicates a potential upside of 27.2%. Trading has ranged between 9,499 (52 week low) and 12,828 (52 week high) with an average of 1,471,870 shares exchanging hands daily. The market capitalisation at the time of writing is £164,274,650,540.
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, the Americas and Asia, Africa and Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
AstraZeneca plc 27.2% potential upside indicated by Barclays
- Written by: Charlotte Edwards
Latest Company News
AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival.
AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options.
The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials.
AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative to IV infusion.
High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally well tolerated.
In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus TACE alone in embolisation-eligible unresectable hepatocellular carcinoma, with an interim trend toward overall survival benefit.
